Triple
T4784927
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | REGN-EB3 |
E106452
|
entity |
| Predicate | hasComponent |
P35
|
FINISHED |
| Object |
odesivimab
Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
|
E468965
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: odesivimab | Statement: [REGN-EB3, hasComponent, odesivimab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: odesivimab Context triple: [REGN-EB3, hasComponent, odesivimab]
-
A.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
-
B.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
C.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
D.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
E.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: odesivimab Triple: [REGN-EB3, hasComponent, odesivimab]
Generated description
Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: odesivimab Target entity description: Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
A.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
-
B.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
-
C.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
D.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
E.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69bd43f4a9588190bf73e20bc27c03cc |
completed | March 20, 2026, 12:56 p.m. |
| NER | Named-entity recognition | batch_69bd65ae49ec81908f16248d22d1155f |
completed | March 20, 2026, 3:20 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69be43dbdec88190817845e7930a18f6 |
completed | March 21, 2026, 7:08 a.m. |
| NEDg | Description generation | batch_69be447c21d48190ab57c8761e733ff4 |
completed | March 21, 2026, 7:10 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69be45f5ebec8190b62c428b465d1bd9 |
completed | March 21, 2026, 7:17 a.m. |
Created at: March 20, 2026, 1:22 p.m.